Reference

Incidence and determinants of migraine prophylactic medication in the Netherlands

Incidence and determinants of migraine prophylactic medication in the Netherlands. Rahimtoola, H.; Buurma, H.; Tijssen, C. C.; Leufkens, H. G.; Egberts, A. C. G. (SIR Institute for Pharmacy Practice Research, Leiden, Neth.). European Journal of Clinical Pharmacology, 58(2), 149-155 (English) 2002 Springer-Verlag. CODEN: EJCPAS. ISSN: 0031-6970. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Objective: To est. and examine the incidence and determinants of initiation of migraine-prophylactic therapy as well as the corresponding drug of choice over a period of 5 yr following the use of specific abortive migraine drugs. Methods: By accessing data from a large prescription database, an identification of patients treated with ergotamine or a triptan from 1 Jan. 1994 to 31 Dec. 1998 was made. The cumulative incidence of initiation of migraine-prophylactic drugs (b-blockers, serotonin antagonists, specific calcium antagonists, amitriptyline, clonidine and valproic acid) was estd. in patients following the use of ergotamine or a triptan. An assessment of the migraine-prophylactic drug of first choice was also performed. A few baseline determinants were analyzed to highlight a possible assocn. with the initiation of prophylactic therapy: age, gender, type of abortive migraine drug use and year of prophylaxis. Addnl. determinants included the anal. of drug-utilization patterns, such as the consumption and switch patterns of abortive migraine drug use as well as co-medication use prior to prophylaxis. For this particular anal. a ref. group (patients not having commenced prophylaxis) was selected from the initial study population. Results: After having satisfied eligibility criteria, a total of 3999 first-time users of ergotamine and triptans were included of whom 479 (12%) had initiated migraine-prophylactic therapy. This corresponded to an incidence d. of 6.0 per 100 person-years and was highest for patients younger than 45 yr and for multiple abortive migraine drug users. The incidence fell considerably from 12.0 person-years in 1994 to 5.1 person-years in 1998. More than half of the patients had been prescribed a b-blocker as the migraine-prophylactic drug of first choice by both general practitioners and neurologists. The use of antidepressants and/or benzodiazepines and oral contraceptives was significantly higher in patients starting prophylaxis compared with those who did not. The consumption of abortive migraine drug use (4.0 defined daily doses per mo vs. 3.7 defined daily doses per mo), and switch patterns (27.1% vs. 30.9%) were similar for patients starting and not starting prophylaxis. Conclusion: The overall incidence of initiation of migraine-prophylactic therapy following the use of abortive migraine analgesics was 6.0% per yr and fell considerably during 5 yr of the study. Beta-blockers were the migraine-prophylactic drugs of first choice for general practitioners and neurologists. 113-15-5 and 139264-17-8 are just another two chemicals used in this study. In our study we could not det. any factors clearly assocd. with the initiation of migraine prophylaxis besides prior use of antidepressants and benzodiazepines. A future assessment of the usage patterns of migraine-prophylactic drugs may provide detailed information concerning the effectiveness and tolerability. .

Zolmitriptan (Zomig)

Zolmitriptan (Zomig).Several substances are used for example 139264-17-8 which is its cas registry number. Rapoport, Alan M.; Bigal, Marcelo E.; Tepper, Stewart J.; Sheftell, Fred D. (College of Physicians and Surgeons, Columbia University, New York, NY, USA). Expert Review of Neurotherapeutics, 4(1), 33-41 (English) 2004 Future Drugs Ltd. CODEN: ERNXAR. ISSN: 1473-7175. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 63 A review. New triptans are being released in rapid succession with each addn. demonstrating some specific pharmacokinetic properties, which may be translated into clin. advantages. Zolmitriptan (Zomig) offers a range of alternatives to migraine sufferers. The conventional tablet is consistently effective across a wide range of migraine subtypes. The orally disintegrating tablet offers an effective option for those migraineurs who are nauseated or need to take their medication earlier in the course of their migraine. Since it can be taken without fluid, the orally disintegrating tablet may be consistently used early in the migraine attack when the pain is still mild. The nasal spray aggregates all the benefits of the oral formulations and has a faster onset of action. The 5-mg dose of all three forms of zolmitriptan offers addnl. benefits over the 2.5-mg dose at early time points. The physician can now choose the optimum route of delivery of zolmitriptan to stop the headache, increase the likelihood of reducing disability and restore the patient to complete functionality. .